Retatrutide
Final price and live stock are confirmed on the partner page before checkout.
Entry concentration for initial titration and pilot metabolic-pathway protocols.
Retatrutide (LY3437943) research compound - a next-generation triple agonist targeting the GLP-1, GIP, and glucagon (GCG) receptors. Studied in metabolic, obesity, and incretin-pathway research as the successor to single- and dual-agonist peptides such as Semaglutide and Tirzepatide. For laboratory research purposes only.
Real Certificate of Analysis from Baltic Peptides · View all COAs
In stock now at our partner Baltic Peptides - GLP-1/GIP/glucagon triple agonist.
Order Retatrutide at Baltic PeptidesSKU: BBL-209-5mg
Checkout: Current partner listing and availability
Product Overview
Retatrutide (LY3437943) research compound - a next-generation triple agonist targeting the GLP-1, GIP, and glucagon (GCG) receptors. Studied in metabolic, obesity, and incretin-pathway research as the successor to single- and dual-agonist peptides such as Semaglutide and Tirzepatide. For laboratory research purposes only.
Every batch is tested by independent EU laboratories using HPLC for purity verification and mass spectrometry for sequence confirmation. A Certificate of Analysis is issued for each batch and ships with your order.
Alternative Research Intensities
*Independent research variants for specific volumetric study parameters.
Related Research Peptides
Tirzepatide
Tirzepatide 5mg